AzurRx BioPharma Inc (NASDAQ:AZRX) has been given an average broker rating score of 1.00 (Strong Buy) from the one analysts that provide coverage for the company, Zacks Investment Research reports. One investment analyst has rated the stock with a strong buy rating.
Brokers have set a 12 month consensus target price of $8.25 for the company, according to Zacks. Zacks has also assigned AzurRx BioPharma an industry rank of 98 out of 265 based on the ratings given to related companies.
Separately, HC Wainwright reaffirmed a “buy” rating and issued a $8.00 price objective on shares of AzurRx BioPharma in a report on Thursday, September 28th.
A number of hedge funds have recently bought and sold shares of the stock. IHT Wealth Management LLC lifted its holdings in AzurRx BioPharma by 15.3% in the second quarter. IHT Wealth Management LLC now owns 3,498 shares of the company’s stock worth $486,000 after purchasing an additional 464 shares during the period. Susquehanna International Group LLP acquired a new stake in AzurRx BioPharma in the third quarter worth about $131,000. Ardsley Advisory Partners acquired a new stake in AzurRx BioPharma in the second quarter worth about $141,000. Finally, Parsons Capital Management Inc. RI lifted its holdings in AzurRx BioPharma by 37.2% in the third quarter. Parsons Capital Management Inc. RI now owns 254,263 shares of the company’s stock worth $1,015,000 after purchasing an additional 68,920 shares during the period. 8.18% of the stock is owned by institutional investors and hedge funds.
TRADEMARK VIOLATION WARNING: This report was first published by American Banking News and is owned by of American Banking News. If you are accessing this report on another site, it was illegally stolen and republished in violation of international copyright laws. The original version of this report can be read at https://www.americanbankingnews.com/2017/12/03/zacks-azurrx-biopharma-inc-azrx-receives-average-rating-of-strong-buy-from-brokerages.html.
About AzurRx BioPharma
AzurRx BioPharma, Inc is a clinical development-stage biopharmaceutical company. The Company is engaged in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal (GI) disorders. The Company’s product pipeline consists of two therapeutic proteins, such as MS1819 and AZX1101.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AzurRx BioPharma Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AzurRx BioPharma Inc and related companies with MarketBeat.com's FREE daily email newsletter.